Survival outcomes and treatment patterns in myelofibrosis in the
JAK
inhibitor era
Juan‐Carlos Hernández‐Boluda, Eduardo Arellano‐Rodrigo, Manuel Pérez‐Encinas, José‐María Raya, María‐Teresa Gómez‐Casares, Francisca Ferrer‐Marín, Alberto Hernández‐Sánchez, María‐Laura Fox, Anna Angona, Beatriz Cuevas, María‐Isabel Mata‐Vázquez, Rosa Ayala, Natalia de las Heras, Elvira Mora, Valentín García‐Gutiérrez, Alicia Senín, Jasson Villarreal, Blanca Xicoy, Raúl Pérez‐López, María García‐Fortes, Sonia González de Villambrosia, Elena Magro, María‐José Ramírez, Paula Gómez, Angel Ramírez‐Payer, Clara Martínez‐Valverde, Lucía Pérez‐Lamas, Carmen García‐Hernández, Mercedes Gasior, Luis‐Miguel Juárez‐Salcedo, Francisco Ibáñez, María‐Luisa Antelo, Lucía Guerrero, Alberto Alvarez‐Larrán, Arturo Pereira, Summary
Data on real‐world survival and treatment patterns in large, unselected myelofibrosis (MF) cohorts remain limited. We analysed 1649 patients with MF diagnosed from 2010 onwards and included in the Spanish Myelofibrosis Registry across 64 centres. Janus kinase (JAK) inhibitors were administered to approximately half of the patients. Among those aged ≤70 years with intermediate‐2/high‐risk International Prognostic Scoring System (IPSS), only 25% ultimately underwent transplantation. Median survival was 6.6 years, with no significant differences between primary and secondary MF; acute leukaemia was the most frequent cause of death, accounting for 20% of cases. Compared with a matched general population, relative survival at 5 and 10 years was 68% and 44% respectively. The reduction in relative survival was more pronounced in patients aged >65 years and in male patients, two subgroups that also exhibited a higher burden of comorbidities and a greater frequency of high molecular risk mutations. Remarkably, patients in the high‐risk IPSS category had a 10‐year relative survival of only 12%; however, survival reduction was not confined to high‐risk disease, with divergence from expected survival emerging early among lower‐risk categories. These findings highlight the persistent impact of MF on life expectancy in the contemporary JAK inhibitor era and the need for improvement in its overall management.